Common cancer drugs may offer treatment for type 1 diabetesNovember 19th, 2008 - 12:28 pm ICT by ANI
Washington, Nov 19 (ANI): A new study from University of California, San Francisco has shown that two common cancer drugs may offer treatment option for type 1 diabetes.
The research team showed that two common cancer drugs Imatinib and Sunitnib, sold as Gleevec and Sutent, respectively could effectively block and reverse type 1 diabetes in mice.
“The findings suggest that kinase inhibitors successfully used in cancer may provide an important new therapeutic approach for treatment of new onset type 1 diabetes and potentially other autoimmune disorders,” said Teodora Staeva, Ph.D., JDRF Director of Immunology.
These drugs are used to treat cancer by blocking tyrosine kinases, an enzyme that modifies cells” signalling proteins through a simple biochemical change.
Kinases trigger cell growth, and it is widely believed that tyrosine kinases are a contributing factor to autoimmune diseases and cancer.
The researchers treated non-diabetic mice prone to developing diabetes with imatinib or sunitinib,
The findings revealed that the drugs prevented the onset of diabetes past the seven-week treatment.
The mice that had already developed diabetes were treated with the drugs and results concluded that after two months of treatment, 80 percent no longer had diabetes.
The study is published in The Proceedings of the National Academy of Sciences. (ANI)
- Growth factor targeted by cancer drugs also prevents heart problem - Jan 12, 2010
- Liver, not brain, may be source of Alzheimer's plaques - Mar 04, 2011
- Researchers cure type 1 diabetes in mice - Apr 09, 2010
- New treatment strategy effective for certain lung cancers - Mar 11, 2011
- Major advance in fight against autoimmune diseases and allergies - Apr 24, 2011
- Why don't you reduce cancer drug price, SC asks Novartis - Sep 11, 2012
- Now, a one-two drug punch approach to KO a lethal cancer - Jun 08, 2009
- Molecular switch that helps pancreatic cancer beat drugs identified - Jan 29, 2010
- Marmite helps heart attack victims live longer - Dec 07, 2010
- 'Smart' lung cancer drug shows promise - Oct 28, 2010
- BP drug lowers weight in spite of high fat diet - Apr 13, 2012
- Drug-chemo combo doubles survival in high-risk childhood leukaemia patients - Oct 07, 2009
- New experimental drug slows down growth of ovarian cancer - Apr 16, 2011
- Gene therapy may help cure diabetes - Jun 22, 2010
- Cell population responsible for body's immune response identified - Mar 07, 2011
Tags: autoimmune diseases, autoimmune disorders, california san francisco, cancer drugs, diabetes, diabetic mice, gleevec, imatinib, jdrf, national academy of sciences, onset type, proceedings of the national academy, proceedings of the national academy of sciences, proteins, sutent, therapeutic approach, treatment option, type 1 diabetes, tyrosine kinases, university of california san francisco